Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

State Street SPDR Bloomberg 1-3 Month T-Bill ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Zimmer Biomet Holdings Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc pays a 0.98% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.

BILZBH
Sector
Fixed IncomeHealth
52-Week High
$91.77$107.71
52-Week Low
$91.27$79.58
Market Cap
$18.65B
Enterprise Value
$25.72B
Dividend Yield
0.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.

As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.

The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH